TME-SW
01698
XIAOMI-W
01810
BOSS ZHIPIN-W
02076
TENCENT
00700
JD HEALTH
06618
(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -22.46%3.95B | -16.77%10.48B | -18.89%5.09B | -12.58%12.6B | -12.40%6.27B | -6.33%14.41B | 25.47%7.16B | 8.04%15.38B | -7.11%5.71B | -5.84%14.24B |
Operating income | -22.46%3.95B | -16.77%10.48B | -18.89%5.09B | -12.58%12.6B | -12.40%6.27B | -6.33%14.41B | 25.47%7.16B | 8.04%15.38B | -7.11%5.71B | -5.84%14.24B |
Cost of sales | 24.76%-3.52B | 19.17%-9.45B | 20.73%-4.68B | 12.28%-11.69B | 11.50%-5.9B | 6.00%-13.32B | -22.18%-6.67B | -8.48%-14.17B | 2.93%-5.46B | 5.58%-13.07B |
Operating expenses | 24.76%-3.52B | 19.17%-9.45B | 20.73%-4.68B | 12.28%-11.69B | 11.50%-5.9B | 6.00%-13.32B | -22.18%-6.67B | -8.48%-14.17B | 2.93%-5.46B | 5.58%-13.07B |
Gross profit | 3.71%425.82M | 14.15%1.04B | 10.27%410.59M | -16.33%908.49M | -24.53%372.33M | -10.22%1.09B | 97.35%493.35M | 3.18%1.21B | -52.13%249.99M | -8.63%1.17B |
Selling expenses | -3.61%-52.7M | -20.04%-139.65M | -8.59%-50.86M | 50.05%-116.34M | 44.01%-46.84M | 7.09%-232.91M | -11.79%-83.66M | -35.97%-250.7M | -15.20%-74.84M | 24.47%-184.37M |
Administrative expenses | 0.49%-212.48M | -2.10%-498.26M | 22.36%-213.53M | 15.47%-488.02M | 21.76%-275.03M | 14.14%-577.32M | -36.89%-351.54M | 13.02%-672.36M | 35.80%-256.8M | 11.39%-772.98M |
Research and development expenses | -4.10%-129.12M | 4.04%-306.56M | 35.06%-124.04M | 21.77%-319.47M | -61.89%-190.99M | -99.04%-408.36M | -14.76%-117.97M | -5.20%-205.17M | -234.80%-102.8M | -38.72%-195.03M |
Profit from asset sales | --6.69M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Impairment and provision | -3,758.12%-9.03M | -52.54%-28.88M | -107.69%-234K | -184.68%-18.93M | 33.95%3.04M | 202.40%22.36M | 114.23%2.27M | 18.46%-21.83M | ---15.96M | -927.35%-26.77M |
-Other impairment is provision | -3,758.12%-9.03M | -52.54%-28.88M | -107.69%-234K | -184.68%-18.93M | 33.95%3.04M | 202.40%22.36M | 114.23%2.27M | 18.46%-21.83M | ---15.96M | -927.35%-26.77M |
Special items of operating profit | 25.45%114.28M | 7.58%219.5M | 32.55%91.1M | 8.12%204.04M | -13.79%68.73M | 26.47%188.7M | 101.61%79.72M | 14,336.93%149.2M | -20.64%39.54M | -100.50%-1.05M |
Operating profit | 26.94%143.47M | 66.78%283.15M | 264.39%113.02M | 116.78%169.77M | -410.11%-68.75M | -62.45%78.32M | 113.78%22.17M | 2,691.64%208.58M | -310.52%-160.86M | -103.36%-8.05M |
Financing cost | 11.69%-59.86M | -3.14%-120.51M | -8.82%-67.78M | -1.02%-116.84M | 0.78%-62.29M | 46.60%-115.66M | 47.11%-62.78M | -47.13%-216.58M | -103.96%-118.68M | -10.59%-147.2M |
Share of profits of associates | -110.44%-59.93M | -3,123.33%-82.07M | -5,528.06%-28.48M | 60.99%-2.55M | -123.08%-506K | -3,007.62%-6.53M | 119.86%2.19M | 98.74%-210K | -58.23%-11.04M | -205.13%-16.72M |
Share of profit from joint venture company | 57.85%-1.28M | 17.74%-3.12M | 50.56%-3.04M | -85.41%-3.79M | -97.34%-6.16M | 88.27%-2.04M | 60.18%-3.12M | -75.38%-17.41M | -4,139.18%-7.84M | -501.70%-9.93M |
Earning before tax | 63.28%22.4M | 66.24%77.46M | 109.96%13.72M | 201.49%46.6M | -231.53%-137.7M | -79.18%-45.91M | 86.08%-41.54M | 85.91%-25.62M | -2,709.02%-298.42M | -250.66%-181.89M |
Tax | 12.70%-1.27M | -22.05%-8.01M | -64.45%-1.46M | -12,246.30%-6.56M | 76.00%-886K | -98.56%54K | -183.98%-3.69M | -75.41%3.76M | 334.29%4.4M | 242.50%15.28M |
After-tax profit from continuing operations | 72.31%21.13M | 73.48%69.46M | 108.85%12.26M | 187.30%40.04M | -206.43%-138.59M | -109.72%-45.86M | 84.62%-45.23M | 86.88%-21.87M | -2,461.65%-294.03M | -233.08%-166.62M |
Earning after tax | 72.31%21.13M | 73.48%69.46M | 108.85%12.26M | 187.30%40.04M | -206.43%-138.59M | -109.72%-45.86M | 84.62%-45.23M | 86.88%-21.87M | -2,461.65%-294.03M | -233.08%-166.62M |
Minority profit | 81.94%19.54M | 163.84%45.98M | 118.50%10.74M | 180.26%17.43M | -139.73%-58.04M | -288.21%-21.71M | 74.60%-24.21M | 127.09%11.54M | -715.30%-95.33M | -178.11%-42.59M |
Profit attributable to shareholders | 4.27%1.59M | 3.83%23.48M | 101.89%1.52M | 193.64%22.61M | -283.27%-80.55M | 27.71%-24.15M | 89.42%-21.02M | 73.07%-33.4M | -6,429.64%-198.7M | -275.49%-124.03M |
Dividend per share | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 0.00%0.003 | ---- | --0.003 |
Basic earnings per share | 0.00%0.0005 | 2.90%0.0071 | 102.05%0.0005 | 193.24%0.0069 | -281.25%-0.0244 | 36.75%-0.0074 | 91.47%-0.0064 | 80.66%-0.0117 | -4,900.00%-0.075 | -275.36%-0.0605 |
Diluted earnings per share | 0.00%0.0005 | 2.90%0.0071 | 102.05%0.0005 | 193.24%0.0069 | -281.25%-0.0244 | 36.75%-0.0074 | 91.47%-0.0064 | 80.66%-0.0117 | -4,900.00%-0.075 | -321.61%-0.0605 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
Auditor | -- | KPMG | -- | KPMG | -- | KPMG | -- | KPMG | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.